NYSE: SQZSqz Biotechnologies Co Stock
$0.57-0.02 (-3.39%)
Updated May 26, 2023
SQZ Price
$0.57
Fair Value Price
N/A
Market Cap
$16.93M
52 Week Low
$0.53
52 Week High
$4.02
P/E
-0.22x
P/B
0.42x
P/S
0.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.61M
Earnings
-$76.11M
Gross Margin
100%
Operating Margin
-408.99%
Profit Margin
-409%
Debt to Equity
0.82
Operating Cash Flow
-$87M
Beta
1.26
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SQZ Overview
SQZ Biotechnologies Company is a clinical-stage biotechnology company developing cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. SQZ Biotechnologies was incorporated in 2013 and is headquartered in Watertown, MA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SQZ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SQZ is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SQZ is good value based on its book value relative to its share price (0.42x), compared to the US Biotechnology industry average (5.18x)
P/B vs Industry Valuation
SQZ is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SQZ due diligence checks available for Premium users.
Be the first to know about important SQZ news, forecast changes, insider trades & much more!
SQZ News
Valuation
SQZ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
11.86x
Market
54.23x
SQZ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
5.18x
SQZ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SQZ's financial health
Profit margin
Revenue
$0.0
Net Income
-$17.7M
Profit Margin
0%
SQZ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SQZ's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$73.2M
Liabilities
$33.0M
Debt to equity
0.82
SQZ's short-term assets ($44.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SQZ's short-term assets ($44.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SQZ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.8M
Investing
-$65.0k
Financing
$0.0
SQZ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SQZ vs Biotech Stocks
Sqz Biotechnologies Co Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.